Shanghai RAAS Blood Products Co., Ltd. (SHE:002252)

China flag China · Delayed Price · Currency is CNY
5.52
+0.05 (0.91%)
Apr 28, 2026, 3:04 PM CST
-17.86%
Market Cap 36.19B
Revenue (ttm) 7.35B
Net Income (ttm) 1.58B
Shares Out 6.56B
EPS (ttm) 0.24
PE Ratio 23.00
Forward PE 19.71
Dividend 0.05 (0.88%)
Ex-Dividend Date Feb 10, 2026
Volume 28,271,402
Average Volume 26,956,840
Open 5.57
Previous Close 5.47
Day's Range 5.46 - 5.57
52-Week Range 5.43 - 7.26
Beta 0.44
RSI 31.08
Earnings Date Apr 29, 2026

About SHE:002252

Shanghai RAAS Blood Products Co., Ltd., together with its subsidiaries, produces and sells blood products in China and internationally. The company offers ALBURAAS, which is albumin prepared from human plasma; GAMARAAS, a human immunoglobulin product for intravenous injections; HEMORAAS, a human coagulation factor VIII product; PROTHORAAS, a human prothrombin complex; FIBRORAAS, a human fibrinogen; FIBINGLURAAS, a fibrin sealant for humans; and THROMBIRAAS, a human thrombin product. It also provides specific immune, human tetanus immunoglobulin... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1988
Employees 4,045
Stock Exchange Shenzhen Stock Exchange
Ticker Symbol 002252
Full Company Profile

Financial Performance

In 2025, SHE:002252's revenue was 7.35 billion, a decrease of -10.13% compared to the previous year's 8.18 billion. Earnings were 1.58 billion, a decrease of -28.10%.

Financial Statements

News

There is no news available yet.